Industry Insights - Pharma & Life Sciences

ErbB1 kinase is the cell-surface receptor for epidermal growth factor. Its dysfunction has been implicated in diseases such as cancer. ...

Effective drug discovery depends on a deep understanding of the function and therapeutic potential of a compound. ...

The first marketed selective T-type calcium channel blocker mibefradil was withdrawn due to adverse drug interactions. ...

Most traditional drugs act on more than one target, exhibiting a complex, multifaceted pharmacological profile. ...

In silico techniques require exhaustive data and sophisticated, well-structured informatics tools to help scientists gain insights of compound behavior. ...

Why is the World Health Organization concerned about a post-antibiotic era in which common infections can kill? ...

Translational medicine is a powerful concept that has had an evolving definition. ...

Cancer immunotherapy shows considerable promise as an effective treatment, especially for cytotoxic-resistant cancers such as melanoma. ...

Spontaneous reports of adverse events are a core source of information. They offer a unique, unrestricted perspective on drug performance. ...

Cancer is often viewed as one monolithic disease, but every cancer is unique. Therapies with accurate diagnosis are needed to effectively fight the disease ...

Biases and heterogeneity in the data of spontaneous adverse event reporting systems can make it hard to gain the insights to inform decisions. ...

Despite growing scientific insight and technological investment, attempts to develop novel therapies still show limited success. ...

With increased focus on literature monitoring, pharmacovigilance groups must analyze existing processes to achieve efficiencies and maintain compliance. ...

Biological researchers face growing body of scientific literature that they must search through in order to keep up with developments in their field. ...

Preclinical safety programs often follow a standard template to determine off-target effects. ...